Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 18;66(1):e0149321.
doi: 10.1128/AAC.01493-21. Epub 2021 Oct 18.

Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?

S Baklouti  1   2 , S Marolleau  2 , P Chavanet  3 , E Bonnet  4 , D Concordet  2 , P Gandia  1   2
Affiliations

Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?

S Baklouti et al. Antimicrob Agents Chemother. .
No abstract available

Keywords: dalbavancin; drug dosing adjustment; osteoarticular infections; total concentrations.

PubMed Disclaimer

Conflict of interest statement

We declare no conflicts of interest.

Figures

FIG 1
FIG 1
Dalbavancin plasma kinetic profiles (n = 10,000) simulated with the population pharmacokinetic model published by Cojutti et al. (1) for 1,500 mg perfused for 30 min. The median kinetic profile is indicated by the white curve. The “extreme” profiles found in less than 5% and 95% of the population are indicated by the black curves. The black squares represent observed trough concentrations for 33 patients with osteoarticular infection treated with 1,500 mg perfused over 30 min.
See this image and copyright information in PMC

References

    1. Cojutti PG, Rinaldi M, Zamparini E, Rossi N, Tedeschi S, Conti M, Pea F, Viale P. 2021. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections. Antimicrob Agents Chemother 65:e02260-20. doi:10.1128/AAC.02260-20. - DOI - PMC - PubMed
    1. Buckwalter M, Dowell JA. 2005. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 45:1279–1287. doi:10.1177/0091270005280378. - DOI - PubMed
    1. Dash RP, Babu RJ, Srinivas NR. 2017. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infect Dis (Lond) 49:483–492. doi:10.1080/23744235.2017.1296968. - DOI - PubMed
    1. Benet LZ, Hoener B-a. 2002. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115–121. doi:10.1067/mcp.2002.121829. - DOI - PubMed
    1. Toutain PL, Bousquet-Melou A. 2002. Free drug fraction vs. free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther 25:460–463. doi:10.1046/j.1365-2885.2002.00442.x. - DOI - PubMed

MeSH terms